{
    "clinical_study": {
        "@rank": "107436", 
        "acronym": "NTX-SBX", 
        "arm_group": [
            {
                "arm_group_label": "Naltrexone intramuscular suspension", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Buprenorphine-naloxone", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Voluntarily unmedicated", 
                "arm_group_type": "No Intervention", 
                "description": "Participants in this group are opioid dependent but express no interest in medical treatment at time of inclusion. They consent to a limited collection of data in the study and are not randomized to a study medication."
            }
        ], 
        "brief_summary": {
            "textblock": "Persons dependent on opioids like heroin, morphine, or codeine have a high risk of overdose\n      and overdose death. This risk is elevated even further following discharge from treatment or\n      correctional institutions where patients have been detoxified. At the moment,\n      state-of-the-art treatment is based on maintaining the dependence on opioids by daily intake\n      of opioid medications like methadone or buprenorphine. Recently, a medication containing the\n      blocking agent naltrexone was approved in the US; this does not maintain dependence but\n      instead blocks heroin and other opioids for 28 days after intramuscular administration. This\n      study will conduct a 12-week randomized comparison of naltrexone intramuscular suspension\n      (XL-NTX) with daily buprenorphine-naloxone in OMT. Medication will start preceding discharge\n      from a treatment or correctional facility to participating catchment regions in Norway. The\n      main hypotheses are that XL-NTX will do equally well as - or better than - OMT on the\n      proportion of biological samples negative for opioids, retention, self-reported use of\n      alcohol and illicit drugs. Following the 12-week randomized period, there will be a 36-week\n      period where participants can receive the study medication of their choice. In addition to\n      the randomized groups, persons who fulfill inclusion criteria but decline medical treatment\n      for opioid dependence will be asked to participate in an unrandomized control group without\n      study medication and with less frequent data collection. After the end of the study, data\n      from national registry databases can be collected for a further 12 months on outcomes such\n      as recidivism, mortality and morbidity."
        }, 
        "brief_title": "Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Opioid Dependence", 
        "condition_browse": {
            "mesh_term": "Opioid-Related Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Opioid dependence (DSM-IV TR)\n\n          -  Age 18 or above\n\n          -  Applied & Approved for Norway's national OMT program\n\n          -  Discharge within 30 days of inclusion from a controlled environment; e.g. inpatient\n             treatment or correctional (prison) facility\n\n          -  Voluntarily seeking treatment for opioid dependence\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast-feeding\n\n          -  Acute or recurring severe psychiatric disorder, e.g. psychosis, suicidality\n\n          -  Serious debilitation of liver or renal function (e.g. Child-Pugh level C)\n\n          -  Use of excluded medication\n\n          -  Known intolerance to study drugs or their ingredients\n\n          -  Employment in firm manufacturing one of the study drugs or close relation to such\n             person"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01717963", 
            "org_study_id": "2011-002858-31", 
            "secondary_id": "204725-1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Naltrexone intramuscular suspension", 
                "description": "A standard dosage of 380 mg / month of naltrexone intramuscular suspension will be administered", 
                "intervention_name": "Naltrexone intramuscular suspension", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Long-acting naltrexone", 
                    "Extended-release naltrexone", 
                    "XR-NTX", 
                    "Vivitrol"
                ]
            }, 
            {
                "arm_group_label": "Buprenorphine-naloxone", 
                "description": "Buprenorphine-naloxone is administered daily and provided in accordance with existing guidelines for OMT in Norway (treatment-as-usual).", 
                "intervention_name": "Buprenorphine-naloxone", 
                "intervention_type": "Drug", 
                "other_name": "Suboxone"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Buprenorphine", 
                "Analgesics, Opioid", 
                "Naltrexone", 
                "Naloxone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 3, 2013", 
        "link": [
            {
                "description": "Website for the Univ of Oslo Naltrexone study group (in Norwegian)", 
                "url": "http://naltrekson.no"
            }, 
            {
                "description": "Webpage of the study Sponsor: The Norwegian Centre for Addiction Research, Univ of Oslo", 
                "url": "http://www.seraf.uio.no/"
            }
        ], 
        "location": [
            {
                "contact": {
                    "email": "lars.tanum@ahus.no", 
                    "last_name": "Lars Tanum, MD, PhD, DmSci"
                }, 
                "facility": {
                    "address": {
                        "city": "Oslo", 
                        "country": "Norway", 
                        "state": "Akershus"
                    }, 
                    "name": "Akershus University Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Lars Tanum, MD, PhD, DmSci", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Zill-e-Huma Latif, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "arild.opheim@helse-bergen.no", 
                    "last_name": "Arild Opheim"
                }, 
                "facility": {
                    "address": {
                        "city": "Bergen", 
                        "country": "Norway", 
                        "state": "Hordaland"
                    }, 
                    "name": "Haukeland University Hospital"
                }, 
                "investigator": {
                    "last_name": "Ola J\u00f8sendal, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ness@sus.no", 
                    "last_name": "Sverre Nesv\u00e5g, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Stavanger", 
                        "country": "Norway", 
                        "state": "Rogaland"
                    }, 
                    "name": "Stavanger University Hospital"
                }, 
                "investigator": {
                    "last_name": "Kristian Larsen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kamsha@siv.no", 
                    "last_name": "Kamni Sharma, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tonsberg", 
                        "country": "Norway", 
                        "state": "Vestfold"
                    }, 
                    "name": "Vestfold Hospital Trust"
                }, 
                "investigator": {
                    "last_name": "Kamni Sharma, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "l.s.stavseth@medisin.uio.no", 
                    "last_name": "Live Sanderud, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Oslo", 
                        "country": "Norway", 
                        "zip": "0407"
                    }, 
                    "name": "Oslo University Hospital, Avdeling for Rus og Avhengighet"
                }, 
                "investigator": [
                    {
                        "last_name": "Peter Krajci, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Live S Stavseth, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "merete.moller@so-hf.no", 
                    "last_name": "Merete M\u00f8ller, RN"
                }, 
                "facility": {
                    "address": {
                        "city": "Fredrikstad", 
                        "country": "Norway", 
                        "state": "\u00d8stfold"
                    }, 
                    "name": "\u00d8stfold Hospital Trust"
                }, 
                "investigator": {
                    "last_name": "Arild Schillinger, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Norway"
        }, 
        "number_of_arms": "3", 
        "official_title": "Optimal Prevention of Overdose Deaths and Opioid Relapse Following Discharge: A Multi-Center RCT of Naltrexone Versus Buprenorphine in Norway", 
        "overall_contact": {
            "email": "lars.tanum@medisin.uio.no", 
            "last_name": "Lars Tanum, MD, PhD"
        }, 
        "overall_contact_backup": {
            "email": "nikolaj.kunoe@medisin.uio.no", 
            "last_name": "Nikolaj Kun\u00f8e, PhD"
        }, 
        "overall_official": {
            "affiliation": "University of Oslo, Norway", 
            "last_name": "Lars Tanum, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Norway: Norwegian Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of biological samples negative/positive for opioid agonists", 
                "safety_issue": "No", 
                "time_frame": "Week 1-12 post discharge"
            }, 
            {
                "measure": "Retention", 
                "safety_issue": "Yes", 
                "time_frame": "First 12 weeks post discharge"
            }, 
            {
                "description": "A mortality comparison is made between medicated groups (pooled together) and the non-medicated group", 
                "measure": "Mortality", 
                "safety_issue": "No", 
                "time_frame": "Week 1-48"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01717963"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Oslo", 
            "investigator_full_name": "Lars Tanum", 
            "investigator_title": "National Coordinating Investigator (PI)", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Use of other substances of abuse", 
                "safety_issue": "No", 
                "time_frame": "Week 1-48"
            }, 
            {
                "description": "Self-reported mental health", 
                "measure": "Mental health", 
                "safety_issue": "No", 
                "time_frame": "Week 1-12 or 1-48"
            }, 
            {
                "description": "Self-reported and/or assessed by study personnel", 
                "measure": "Somatic health", 
                "safety_issue": "No", 
                "time_frame": "Week 1-12 or 1-48 post discharge"
            }, 
            {
                "description": "Psychosocial problems like recidivism, employment, family problems. Self-reported or registry-based.", 
                "measure": "Psychosocial problems", 
                "safety_issue": "No", 
                "time_frame": "Week 1-12, Week 1-48, & Wk 49-100"
            }
        ], 
        "source": "University of Oslo", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "The Research Council of Norway", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Royal Norwegian Ministry of Health", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Norwegian Institute of Public Health", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Oslo University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University Hospital, Akershus", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Haukeland University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Helse Stavanger HF", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Vestfold Hospital Trust", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Ostfold Hospital Trust", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Oslo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}